Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer

• We report an ovarian cancer patient with a prolonged response to immunotherapy. • Comprehensive genomic profiling may detect patients who benefit from immunotherapy. • Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Detalles Bibliográficos
Autores principales: Morse, Christopher B., Elvin, Julia A., Gay, Laurie M., Liao, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510487/
https://www.ncbi.nlm.nih.gov/pubmed/28736741
http://dx.doi.org/10.1016/j.gore.2017.06.013
_version_ 1783250193122066432
author Morse, Christopher B.
Elvin, Julia A.
Gay, Laurie M.
Liao, John B.
author_facet Morse, Christopher B.
Elvin, Julia A.
Gay, Laurie M.
Liao, John B.
author_sort Morse, Christopher B.
collection PubMed
description • We report an ovarian cancer patient with a prolonged response to immunotherapy. • Comprehensive genomic profiling may detect patients who benefit from immunotherapy. • Mutational burden thresholds for ovarian cancer may be lower than other cancers.
format Online
Article
Text
id pubmed-5510487
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55104872017-07-21 Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer Morse, Christopher B. Elvin, Julia A. Gay, Laurie M. Liao, John B. Gynecol Oncol Rep Case Report • We report an ovarian cancer patient with a prolonged response to immunotherapy. • Comprehensive genomic profiling may detect patients who benefit from immunotherapy. • Mutational burden thresholds for ovarian cancer may be lower than other cancers. Elsevier 2017-06-27 /pmc/articles/PMC5510487/ /pubmed/28736741 http://dx.doi.org/10.1016/j.gore.2017.06.013 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Morse, Christopher B.
Elvin, Julia A.
Gay, Laurie M.
Liao, John B.
Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title_full Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title_fullStr Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title_full_unstemmed Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title_short Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
title_sort elevated tumor mutational burden and prolonged clinical response to anti-pd-l1 antibody in platinum-resistant recurrent ovarian cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510487/
https://www.ncbi.nlm.nih.gov/pubmed/28736741
http://dx.doi.org/10.1016/j.gore.2017.06.013
work_keys_str_mv AT morsechristopherb elevatedtumormutationalburdenandprolongedclinicalresponsetoantipdl1antibodyinplatinumresistantrecurrentovariancancer
AT elvinjuliaa elevatedtumormutationalburdenandprolongedclinicalresponsetoantipdl1antibodyinplatinumresistantrecurrentovariancancer
AT gaylauriem elevatedtumormutationalburdenandprolongedclinicalresponsetoantipdl1antibodyinplatinumresistantrecurrentovariancancer
AT liaojohnb elevatedtumormutationalburdenandprolongedclinicalresponsetoantipdl1antibodyinplatinumresistantrecurrentovariancancer

Ejemplares similares